- Home
- AVD vs VIGL Comparison
AVD vs VIGL Comparison
Compare AVD & VIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVD
- VIGL
- Stock Information
- Founded
- AVD 1969
- VIGL 2020
- Country
- AVD United States
- VIGL United States
- Employees
- AVD N/A
- VIGL N/A
- Industry
- AVD Agricultural Chemicals
- VIGL Biotechnology: Pharmaceutical Preparations
- Sector
- AVD Industrials
- VIGL Health Care
- Exchange
- AVD Nasdaq
- VIGL Nasdaq
- Market Cap
- AVD 171.3M
- VIGL 141.1M
- IPO Year
- AVD N/A
- VIGL 2022
- Fundamental
- Price
- AVD $6.05
- VIGL $3.71
- Analyst Decision
- AVD Strong Buy
- VIGL Buy
- Analyst Count
- AVD 3
- VIGL 5
- Target Price
- AVD $16.67
- VIGL $16.60
- AVG Volume (30 Days)
- AVD 292.0K
- VIGL 112.2K
- Earning Date
- AVD 08-08-2024
- VIGL 08-13-2024
- Dividend Yield
- AVD 1.94%
- VIGL N/A
- EPS Growth
- AVD N/A
- VIGL N/A
- EPS
- AVD N/A
- VIGL N/A
- Revenue
- AVD $585,049,000.00
- VIGL N/A
- Revenue This Year
- AVD N/A
- VIGL N/A
- Revenue Next Year
- AVD $4.69
- VIGL N/A
- P/E Ratio
- AVD N/A
- VIGL N/A
- Revenue Growth
- AVD 2.73
- VIGL N/A
- 52 Week Low
- AVD $4.95
- VIGL $2.47
- 52 Week High
- AVD $14.28
- VIGL $9.24
- Technical
- Relative Strength Index (RSI)
- AVD 40.74
- VIGL 52.59
- Support Level
- AVD $5.61
- VIGL $3.20
- Resistance Level
- AVD $6.58
- VIGL $3.84
- Average True Range (ATR)
- AVD 0.24
- VIGL 0.28
- MACD
- AVD 0.15
- VIGL 0.05
- Stochastic Oscillator
- AVD 40.91
- VIGL 77.34
About AVD American Vanguard Corporation ($0.10 Par Value)
American Vanguard Corp is a United States-based diversified specialty and agricultural products company. It manufactures and formulates chemicals for crops, turf and ornamental plants, and human and animal health protection. These chemicals include insecticides, fungicides, herbicides, molluscicides, growth regulators, and soil fumigants, which are marketed in liquid, powder, and granular forms.
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.